498 related articles for article (PubMed ID: 16142014)
1. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes.
Gautier JF; Fetita S; Sobngwi E; Salaün-Martin C
Diabetes Metab; 2005 Jun; 31(3 Pt 1):233-42. PubMed ID: 16142014
[TBL] [Abstract][Full Text] [Related]
2. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes.
Gautier JF; Choukem SP; Girard J
Diabetes Metab; 2008 Feb; 34 Suppl 2():S65-72. PubMed ID: 18640588
[TBL] [Abstract][Full Text] [Related]
3. Enhancing incretin action for the treatment of type 2 diabetes.
Drucker DJ
Diabetes Care; 2003 Oct; 26(10):2929-40. PubMed ID: 14514604
[TBL] [Abstract][Full Text] [Related]
4. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.
Green BD; Gault VA; O'harte FP; Flatt PR
Curr Pharm Des; 2004; 10(29):3651-62. PubMed ID: 15579061
[TBL] [Abstract][Full Text] [Related]
5. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
Diamant M; Bunck MC; Heine RJ
Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
[TBL] [Abstract][Full Text] [Related]
6. [The incretin effect: a new therapeutic target in type 2 diabetes].
Féry F
Rev Med Brux; 2007 Sep; 28(4):329-35. PubMed ID: 17958029
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus.
Meier JJ; Gallwitz B; Nauck MA
BioDrugs; 2003; 17(2):93-102. PubMed ID: 12641488
[TBL] [Abstract][Full Text] [Related]
8. Gut peptides in the treatment of diabetes mellitus.
Vahl TP; D'Alessio DA
Expert Opin Investig Drugs; 2004 Mar; 13(3):177-88. PubMed ID: 15013938
[TBL] [Abstract][Full Text] [Related]
9. Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.
Baggio LL; Drucker DJ
Treat Endocrinol; 2002; 1(2):117-25. PubMed ID: 15765627
[TBL] [Abstract][Full Text] [Related]
10. Incretins: their physiology and application in the treatment of diabetes mellitus.
Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
[TBL] [Abstract][Full Text] [Related]
11. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
Hansotia T; Drucker DJ
Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
[TBL] [Abstract][Full Text] [Related]
12. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
Creutzfeldt W
Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst JJ; Deacon CF
Diabetes; 1998 Nov; 47(11):1663-70. PubMed ID: 9792533
[TBL] [Abstract][Full Text] [Related]
14. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
15. Incretin hormones: Their role in health and disease.
Nauck MA; Meier JJ
Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.
Green BD; Gault VA; Flatt PR; Harriott P; Greer B; O'Harte FP
Arch Biochem Biophys; 2004 Aug; 428(2):136-43. PubMed ID: 15246869
[TBL] [Abstract][Full Text] [Related]
17. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.
Deacon CF; Wamberg S; Bie P; Hughes TE; Holst JJ
J Endocrinol; 2002 Feb; 172(2):355-62. PubMed ID: 11834453
[TBL] [Abstract][Full Text] [Related]
18. Incretin hormones--an update.
Holst JJ; Orskov C
Scand J Clin Lab Invest Suppl; 2001; 234():75-85. PubMed ID: 11713984
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
Pospisilik JA; Martin J; Doty T; Ehses JA; Pamir N; Lynn FC; Piteau S; Demuth HU; McIntosh CH; Pederson RA
Diabetes; 2003 Mar; 52(3):741-50. PubMed ID: 12606516
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.
Holz GG; Chepurny OG
Curr Med Chem; 2003 Nov; 10(22):2471-83. PubMed ID: 14529486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
